Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 5;80(6):glae052.
doi: 10.1093/gerona/glae052.

Skeletal Muscle Aging: Lessons From Teleosts

Tuyen K Quach  1 , Megan F Taylor  2 , Peter D Currie  2   3 , Nir Eynon  2 , Avnika A Ruparelia  1   4
Affiliations
Review

Skeletal Muscle Aging: Lessons From Teleosts

Tuyen K Quach et al. J Gerontol A Biol Sci Med Sci. .

Abstract

Aging is the greatest risk factor for a multitude of age-related diseases including sarcopenia-the loss of skeletal muscle mass and strength-which occurs at remarkable rates each year. There is an unmet need not only to understand the mechanisms that drive sarcopenia but also to identify novel therapeutic strategies. Given the ease and affordability of husbandry, along with advances in genomics, genome editing technologies, and imaging capabilities, teleost models are increasingly used for aging and sarcopenia research. Here, we explain how teleost species such as zebrafish, African turquoise killifish, and medaka recapitulate many of the classical hallmarks of sarcopenia, and discuss the various dietary, pharmacological, and genetic approaches that have been used in teleosts to understand the mechanistic basis of sarcopenia.

Keywords: Age-related pathology; Fish models; Sarcopenia; Skeletal muscle.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1.
Figure 1.
Characteristics of the zebrafish, African turquoise killifish, and medaka.
Figure 2.
Figure 2.
Summary of the hallmarks of sarcopenia pathologies in teleosts.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. 2015;96(3):183–195. https://doi.org/10.1007/s00223-014-9915-y - DOI - PubMed
    1. Yuan S, Larsson SC. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism. 2023;144(155533):155560. https://doi.org/10.1016/j.metabol.2023.155560 - DOI - PubMed
    1. Goodpaster BH, Park SW, Harris TB, et al.. The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059–1064. https://doi.org/10.1093/gerona/61.10.1059 - DOI - PubMed
    1. Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia. Expert Opin Pharmacother. 2019;20(13):1645–1657. https://doi.org/10.1080/14656566.2019.1622093 - DOI - PubMed
    1. Lynch GS. Identifying the challenges for successful pharmacotherapeutic management of sarcopenia. Expert Opin Pharmacother. 2022;23(11):1233–1237. https://doi.org/10.1080/14656566.2022.2076593 - DOI - PubMed